凯因益生伴侣颗粒联合干扰素治疗慢性乙型肝炎的临床疗效研究

The clinical effect of Kain prebiotic partner particles combined with interferon in the treatment of chronic hepatitis B

目的探讨凯因益生伴侣颗粒联合干扰素α-2b治疗慢性乙型肝炎的临床疗效。方法选取2012年2月—2013年2月在邯郸市传染病医院接受治疗的慢性乙型肝炎患者120例,随机分为干预组和对照组,各60例。对照组在基础保肝、降酶支持对症治疗的基础上给予重组人α-2b干扰素治疗,干预组在对照组基础上给予凯因益生伴侣颗粒治疗,检测并比较两组患者的肝功能指标、血清HBs Ag水平、血清HBV-DNA水平、血清HBe Ag/HBe Ab转换率。结果治疗12周后干预组的谷氨酸氨基转移酶(ALT)、天冬氨酸氨基转移酶(AST)、总胆红素(TBi L)低于对照组,差异有统计学意义(P<0.05)。治疗后4周、8周、12周干预组血清HBs Ag水平、血清HBV-DNA水平低于对照组,差异有统计学意义(P<0.05)。治疗后两组不同血清HBs Ag水平的患者血清HBe Ag/HBe Ab转换率比较,差异无统计学意义(P>0.05);治疗后12周,干预组血清HBe Ag/HBe Ab转换率高于对照组,差异有统计学意义(P<0.05)。结论凯因益生伴侣颗粒联合干扰素是慢性乙型肝炎抗病毒治疗的有效药物,与单纯干扰素用药相比,具有明显的改善患者肝功能、降低血清HBs Ag水平及血清DNA水平、降低血清HBe Ag/HBe Ab转换率的效果。

Objective To study the clinical effect of Kain partner particles combined with interferon in the treatment of chronic hepatitis B. Methods In Infectious Disease Hospital of Handan from February 2012 to 2013,120 patients with chronic hepatitis B were selected and randomly devided into treatment group and control group,60 cases in each group. Control group were treated with human recombinant alpha-2b interferon on the basis of protect liver,fall enzyme support symptomatic treatment,treatment group were treated with Kain prebiotic partner particles on the basis of control group. Liver function,serum HBsAg level,serum HBV-DNA level,serum HBeAg/HBeAb conversion rate between the two groups were compared. Results 12 weeks after treatment,ALT,AST,TBiL of treatment group were lower than control group（P〈0. 05）;4,8,12 weeks after treatment serum HBsAg levels and serum HBV-DNA levels of the treatment group were lower than those of the control group（P〈0. 05）. After treatment,serum HBeAg / HBeAb conversion rate between two groups with different HBsAg levels showed no significant differences（P＆gt;0. 05）;12 weeks after treatment,serum HBeAg / HBeAb conversion rate of treatment group was higher than than control group（P〈0. 05）. Conclusion Kain prebiotic partner particles combination with interferon are effective drugs in the treatment of chronic hepatitis B,liver function,serum HBsAg levels and serum DNA level,serum HBeAg/HBeAb conversion rate are better than that of simple interferon treatment.